Latest multiple sclerosis Stories
According to new report from BCC Research,the global market for multiple sclerosis (MS) disease-modifying products reached nearly $10.9 billion in 2013.
Author tells story of adoption gone wrong, a dysfunctional childhood, and living with multiple sclerosis. Orlando, Florida (PRWEB) August 15, 2014 First
-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 -- ROCKVILLE, Md., Aug.
COPENHAGEN, Denmark, Aug.
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition -- ROCKVILLE, Md., July 31, 2014 /PRNewswire/ -- Synthetic
DailyGossip.org reveals in its latest review that a new program, the Natural Multiple Sclerosis Treatment, has been developed for sufferers to access a natural, safe way of stopping multiple sclerosis.
MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store.
Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results ANAHEIM, Calif., July 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.
More Images (1 images) »